Mizuho Downgrades ZoomInfo to Underperform Amidst Revenue Outlook Concerns

Ramit Sethi

Author of "I Will Teach You to Be Rich," focusing on psychology and systems for a rich life without guilt.

Mizuho recently adjusted its rating for ZoomInfo Technologies Inc. (GTM), moving it from a 'Neutral' stance to 'Underperform,' while also reducing the stock's price target. This reevaluation comes on the heels of ZoomInfo's first-quarter 2026 financial disclosure. The company's report highlighted a strategic transition in its business model, which, despite showing better-than-expected earnings per share driven by cost control, presented a less optimistic revenue forecast for the year. Analysts at Mizuho expressed apprehension regarding the efficacy of this new operational direction in sustaining growth amidst changing market dynamics.

The downgrade, announced on May 13, saw ZoomInfo's price target slashed from $10 to $3. Mizuho's analysis pointed to a deteriorating revenue outlook and increased risks associated with ZoomInfo's ongoing business model transformation. The company's Q1 2026 financial results, published on May 11, showed a modest 1.5% year-over-year revenue increase, reaching $310.2 million. This growth was attributed to the company's evolving product pricing and packaging strategies.

Despite the cautious revenue forecast, ZoomInfo managed to surpass adjusted earnings per share expectations, reporting $0.28 against an anticipated $0.26. This positive deviation was largely due to stringent cost management, which boosted the adjusted operating margin by 240 basis points to 35% compared to the previous year. However, the company's management revised its full-year 2026 revenue guidance downwards to between $1.185 billion and $1.205 billion, a significant reduction from the earlier projection of $1.247 billion to $1.267 billion.

This revised guidance was a key factor in Mizuho's decision to lower its rating. The core issue, however, revolved around ZoomInfo's shift from a traditional subscription-based revenue model to one centered on consumption. While Mizuho acknowledges the potential long-term benefits of this transition, analysts are concerned that the revenue generated from the new model might not grow sufficiently to compensate for the revenue loss from customers discontinuing their existing subscriptions.

ZoomInfo Technologies Inc. specializes in providing cloud-based market intelligence platforms for sales, marketing, recruiting, and operations teams. The company leverages artificial intelligence, automation, and proprietary business databases to assist businesses in identifying potential clients, generating leads, and enhancing customer relationships. While ZoomInfo's potential as an investment is recognized, some market observers suggest that other AI-focused stocks might offer better growth prospects with reduced risks.

In sum, Mizuho's re-evaluation of ZoomInfo reflects a cautious outlook on the company's financial trajectory, primarily due to an uncertain revenue growth path stemming from its strategic shift to a consumption-based model, despite strong cost management efforts.

you may like

youmaylikeicon
Analog Devices Strengthens AI Portfolio with Empower Semiconductor Acquisition and Exceeds Q2 Expectations

Analog Devices Strengthens AI Portfolio with Empower Semiconductor Acquisition and Exceeds Q2 Expectations

By Natalie Pace
Key Industrial Stocks See Significant Movement in Wednesday's Pre-Market

Key Industrial Stocks See Significant Movement in Wednesday's Pre-Market

By Dave Ramsey
Key Movements in Consumer Discretionary Stocks Pre-Market on Wednesday

Key Movements in Consumer Discretionary Stocks Pre-Market on Wednesday

By T. Harv Eker
4D Molecular Therapeutics Inc (FDMT): A Deep Dive into a Promising Gene Therapy Stock

4D Molecular Therapeutics Inc (FDMT): A Deep Dive into a Promising Gene Therapy Stock

By Mr. Money Mustache
EVERTEC Demonstrates Robust 8% Revenue Expansion, Driven by Latin American Market Leadership

EVERTEC Demonstrates Robust 8% Revenue Expansion, Driven by Latin American Market Leadership

By Ramit Sethi
Passage Bio's Strategic Review Amidst Gene Therapy Challenges

Passage Bio's Strategic Review Amidst Gene Therapy Challenges

By Scott Pape
Regenxbio's Financial Health and Therapeutic Advances

Regenxbio's Financial Health and Therapeutic Advances

By Mr. Money Mustache
Donnelley Financial (DFIN) Boosts Share Buyback Amid Surging Software Revenue

Donnelley Financial (DFIN) Boosts Share Buyback Amid Surging Software Revenue

By T. Harv Eker
Geopolitical Pressures Impact Walt Disney Company's Q1 Performance

Geopolitical Pressures Impact Walt Disney Company's Q1 Performance

By Vicki Robin
Solid Biosciences: Growth Prospects and Gene Therapy Innovations

Solid Biosciences: Growth Prospects and Gene Therapy Innovations

By Vicki Robin
Ondas: A Deep Dive into its Competitive Landscape in Communications Equipment

Ondas: A Deep Dive into its Competitive Landscape in Communications Equipment

By Ramit Sethi
Tuttle Capital Plans New "Magnificent 10" ETF, Expanding Beyond "Mag 7"

Tuttle Capital Plans New "Magnificent 10" ETF, Expanding Beyond "Mag 7"

By Scott Pape
Analyst Downgrades ONEOK (OKE) to Hold, Citing Valuation Concerns Amidst Mixed Q1 Results

Analyst Downgrades ONEOK (OKE) to Hold, Citing Valuation Concerns Amidst Mixed Q1 Results

By Mr. Money Mustache
Micron Technology's Competitive Landscape in Semiconductor Industry Explored

Micron Technology's Competitive Landscape in Semiconductor Industry Explored

By Scott Pape
Truist Adjusts Insmed (INSM) Target Amidst Market Competition

Truist Adjusts Insmed (INSM) Target Amidst Market Competition

By Chika Uwazie